AngioDynamics, Inc. Q3 2026 Earnings Recap

ANGO Q3 2026 April 2, 2026

Get alerts when ANGO reports next quarter

AngioDynamics delivered another strong quarter, demonstrating sustained top-line growth and expanding profitability driven by robust performance in Med Tech and thrombectomy portfolios. The company continues to execute on strategic priorities, raising full-year guidance for the third consecutive quarter.

Earnings Per Share Beat

$-0.07 vs $-0.11 est.

+36.4% surprise

Revenue Beat

78421000 vs 76766670 est.

+2.2% surprise

Market Reaction

1-Day -13.65%

5-Day -18.76%

30-Day -8.04%

See ANGO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Med Tech segment, led by Auryon, achieved 19th consecutive quarter of double-digit YoY growth, supported by international expansion post-CE Mark.
Thrombectomy portfolio (AlphaVac and AngioVac) grew approximately 18% YoY, with AlphaVac showing record sequential revenue increase and positive clinical adoption.
NanoKnife saw notable growth in disposables and capital, with expanded European indications and a favorable CMS CPT 1 code rollout bolstering market access.
The company reaffirmed its strategic focus on large, high-margin markets amid macro uncertainties, leveraging innovation and clinical milestones.
Full-year revenue and EBITDA guidance were raised for the third straight quarter, reflecting confidence in continued profitable growth.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ANGO on AllInvestView.

Previous Q2 2026